- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
This study is testing a new tablet, AP1189, for people recently diagnosed with rheumatoid arthritis who haven't tried other strong medicines yet. It aims to see how well different doses of AP1189 lower inflammation and improve symptoms when taken with another common arthritis medicine.
For: Rheumatoid ArthritisBulgaria · Czechia · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
This study looks at ways to prevent infusion reactions in people with advanced lung cancer receiving a new combination of medicines. Researchers are testing different medications given before treatment to see if they can reduce side effects when the main cancer drug is given through a drip.
For: EGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerFrance · Spain